-

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
in PRESS RELEASE 2024 onLaunch of two first-in-class medicines in 2023 marks start of exciting phase…
-

Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
in Uncategorized, PRESS RELEASE 2024 on…
PRESS RELEASE 2024
PRESS RELEASE 2024